Market Overview

UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise

Related HOLX
25 Tactical Trades Goldman Sachs Is Watching Amid Earnings Season
Icahn: I Believe It'll All Work Out With Freeport-McMoRan

ISI Group maintained Hologic (NASDAQ: HOLX) with a Strong Buy rating and raised the price target from $25.50 to $27.00.

ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00."

Hologic closed at $23.25 on Monday.

Latest Ratings for HOLX

Nov 2015Leerink SwannMaintainsOutperform
Sep 2015JefferiesMaintainsBuy
Sep 2015BarclaysUpgradesUnderweightEqual-weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters